Multiple sclerosis relapse following gamma knife radiosurgery for meningioma in a patient treated with natalizumab: case report
- 1Division of Neurology, University of Alberta , , ,
Abstract
Objectives: We describe a case of a patient with multiple sclerosis (MS) stable on natalizumab who developed widespread gadolinium-enhancing lesions and clinical relapse seven and eight months after gamma knife radiosurgery (GKRS) for left cerebellar convexity meningioma. We explore how increased blood–brain barrier (BBB) permeability post-GKRS could potentially interfere with the lymphocyte anti-trafficking effect of natalizumab and result in new central nervous system (CNS) inflammation distant from the radiation site.
Methods: Comprehensive analysis of the patient’s chart, brain and spine imaging, serum and cerebrospinal fluid (CSF) profiles was conducted. We compiled a graphical representation of treatment changes, radiologic findings, and GKRS initiation within one timeframe. We conducted a structured literature review to support the discussion of this case and hypothesize possible pathophysiological mechanisms contributing to clinical and radiological findings.
Results: Seven months after GKRS, follow-up brain magnetic resonance imaging (MRI) demonstrated multiple gadolinium-enhancing lesions in both cerebral hemispheres, and repeat imaging one month later revealed new gadolinium-enhancing lesions, correlating with the patient’s clinical relapse. Alternative causes of disease progression, including radiation-induced demyelination, radionecrosis, opportunistic infections, progressive multifocal leukoencephalopathy (PML), and development of anti-natalizumab antibodies, were explored and considered less likely. The patient was switched to ofatumumab with subsequent clinical and radiological stability.
Discussion: Given extensive new inflammatory lesions far from the GKRS site, it seems unlikely that the sole mechanism was radiation-induced neurotoxicity. We hypothesize that late delayed radiation side effects caused by GKRS may have enabled peripheral lymphocytes to enter the CNS, counteracting the effects of natalizumab on blocking lymphocyte trafficking through the BBB and possibly contributing to MS relapse.
Related
- Anti‐CD20 Drugs and Natalizumab Confer Equal Protection Against Progression Independent of Relapse Activity (PIRA) in People With Multiple Sclerosis
- Digital signatures of fatigue and wearing-off symptoms in patients with multiple sclerosis under natalizumab
- Comparison of endoplasmic reticulum chaperone gene expression and dosimetric findings before and after gamma knife radiosurgery in meningioma
- Long-Term Disease Control Following Completion of Cladribine Treatment in Multiple Sclerosis: Extended Follow-Up of the CladStop Cohort.
- Disability-relevant demyelination in multiple sclerosis: five-year evolution following diagnosis
BibTeX
@article{turbinska2026multiple,
title = {{Multiple sclerosis relapse following gamma knife radiosurgery for meningioma in a patient treated with natalizumab: case report}},
author = {Maryna Turbinska and Nabeela Nathoo and Penelope Smyth},
journal = {Frontiers in oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1959731},
url = {https://europepmc.org/article/PMC/PMC13690557},
note = {CC BY},
}
RIS
TY - JOUR
TI - Multiple sclerosis relapse following gamma knife radiosurgery for meningioma in a patient treated with natalizumab: case report
AU - Maryna Turbinska
AU - Nabeela Nathoo
AU - Penelope Smyth
PY - 2026
DA - 2026/10/09
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1959731
UR - https://europepmc.org/article/PMC/PMC13690557
AB - Objectives: We describe a case of a patient with multiple sclerosis (MS) stable on natalizumab who developed widespread gadolinium-enhancing lesions and clinical relapse seven and eight months after gamma knife radiosurgery (GKRS) for left cerebellar convexity meningioma. We explore how increased blood–brain barrier (BBB) permeability post-GKRS could potentially interfere with the lymphocyte anti-trafficking effect of natalizumab and result in new central nervous system (CNS) inflammation distant from the radiation site. Methods: Comprehensive analysis of the patient’s chart, brain and spine imaging, serum and cerebrospinal fluid (CSF) profiles was conducted. We compiled a graphical representation of treatment changes, radiologic findings, and GKRS initiation within one timeframe. We conducted a structured literature review to support the discussion of this case and hypothesize possible pathophysiological mechanisms contributing to clinical and radiological findings. Results: Seven months after GKRS, follow-up brain magnetic resonance imaging (MRI) demonstrated multiple gadolinium-enhancing lesions in both cerebral hemispheres, and repeat imaging one month later revealed new gadolinium-enhancing lesions, correlating with the patient’s clinical relapse. Alternative causes of disease progression, including radiation-induced demyelination, radionecrosis, opportunistic infections, progressive multifocal leukoencephalopathy (PML), and development of anti-natalizumab antibodies, were explored and considered less likely. The patient was switched to ofatumumab with subsequent clinical and radiological stability. Discussion: Given extensive new inflammatory lesions far from the GKRS site, it seems unlikely that the sole mechanism was radiation-induced neurotoxicity. We hypothesize that late delayed radiation side effects caused by GKRS may have enabled peripheral lymphocytes to enter the CNS, counteracting the effects of natalizumab on blocking lymphocyte trafficking through the BBB and possibly contributing to MS relapse.
SN - 2234-943X
ER -